<SEC-DOCUMENT>0001628280-22-024362.txt : 20220906
<SEC-HEADER>0001628280-22-024362.hdr.sgml : 20220906
<ACCEPTANCE-DATETIME>20220906160738
ACCESSION NUMBER:		0001628280-22-024362
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220906
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220906
DATE AS OF CHANGE:		20220906

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35558
		FILM NUMBER:		221228332

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>crdf-20220906.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:9c7e79fd-b44a-4fe9-9350-01d310b3d7b9,g:6c1a1eac-e2dc-4a93-aba9-64cc82ee1060,d:1cb4808ced7b4ff1a509263e38b63f13--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>crdf-20220906</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM180L2ZyYWc6ZmE2ZWJjZDgxOWQ2NDI4M2JiZTk4MzkwNjU4MmU0ODAvdGFibGU6MWYwNGVkYTNjZWJiNDUwMTk3ZjliZWYyZmNlOTBlOWEvdGFibGVyYW5nZToxZjA0ZWRhM2NlYmI0NTAxOTdmOWJlZjJmY2U5MGU5YV8yLTEtMS0xLTM3MjIw_2b8aedcc-909c-446d-b57c-9133a06e61c4">0001213037</ix:nonNumeric><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM180L2ZyYWc6ZmE2ZWJjZDgxOWQ2NDI4M2JiZTk4MzkwNjU4MmU0ODAvdGFibGU6MWYwNGVkYTNjZWJiNDUwMTk3ZjliZWYyZmNlOTBlOWEvdGFibGVyYW5nZToxZjA0ZWRhM2NlYmI0NTAxOTdmOWJlZjJmY2U5MGU5YV8zLTEtMS0xLTM3MjIw_ca57b290-39eb-4c0b-9b91-372f5d0aa471">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="crdf-20220906.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-06</xbrli:startDate><xbrli:endDate>2022-09-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1cb4808ced7b4ff1a509263e38b63f13_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzM0_204f5138-f954-4f21-abbb-3828ea4f9863">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF8yMjg_62a18123-97c5-4d0c-bf92-7e9349a52e3e">September 6, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="crdf-20220906_g1.jpg" alt="crdf-20220906_g1.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:157px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzMw_b43a5dcf-e0df-4506-b822-6574e5ed9dd5">Cardiff Oncology,&#160;Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGFibGU6MjcxYWJhNTIwYzNiNDVmNGI0YWQyMDc3YTViZjFhNjEvdGFibGVyYW5nZToyNzFhYmE1MjBjM2I0NWY0YjRhZDIwNzdhNWJmMWE2MV8wLTAtMS0xLTM3MjIw_893462a9-5ed2-4350-950f-af6f3cb90d6f">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGFibGU6MjcxYWJhNTIwYzNiNDVmNGI0YWQyMDc3YTViZjFhNjEvdGFibGVyYW5nZToyNzFhYmE1MjBjM2I0NWY0YjRhZDIwNzdhNWJmMWE2MV8wLTEtMS0xLTM3MjIw_762cddde-8cbb-40bc-a265-47c8e08ffcb4">001-35558</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGFibGU6MjcxYWJhNTIwYzNiNDVmNGI0YWQyMDc3YTViZjFhNjEvdGFibGVyYW5nZToyNzFhYmE1MjBjM2I0NWY0YjRhZDIwNzdhNWJmMWE2MV8wLTItMS0xLTM3MjIw_dddf9276-95e7-47ef-bae9-a13549b061cf">27-2004382</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzM1_c87f186d-086f-4f22-9716-7805aecd464e">11055 Flintkote Avenue</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzMz_677d2d4b-e8d7-48f2-9f76-685482342ec4">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzM2_3232843f-8471-42ec-b6f0-bd9db3a1fbf2">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzM3_53ff5cae-d5a5-4e09-8824-0137d34430c6">92121</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzI2_603c1e02-1719-4579-8f49-a097c1b5b416">(858)</ix:nonNumeric> <ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzM5_a524b461-8425-43ba-83e6-a69bee302783">952-7570</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160; </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading&#160;Symbol(s)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-right:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGFibGU6NmFmOGVhZGZiMDQzNDU0M2IzNGYyMDNjYzU5ZjgzYTYvdGFibGVyYW5nZTo2YWY4ZWFkZmIwNDM0NTQzYjM0ZjIwM2NjNTlmODNhNl8xLTAtMS0xLTM3MjIw_77ebe5e1-1b26-4f68-8496-dc9e4bc5ebdd">Common Stock</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGFibGU6NmFmOGVhZGZiMDQzNDU0M2IzNGYyMDNjYzU5ZjgzYTYvdGFibGVyYW5nZTo2YWY4ZWFkZmIwNDM0NTQzYjM0ZjIwM2NjNTlmODNhNl8xLTItMS0xLTM3MjIw_40433afd-25b8-42fb-b7b9-88a21b8cc2e8">CRDF</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzI3_f8c13b7c-8bf7-417d-870f-b28f1c1f0e2b">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Written communication pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzMx_67a6bebc-6d52-48ed-8edb-5a794d2676be">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzI4_070746e8-89c6-447c-aaf1-e5e92f1d6e05">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzMy_c5e7b990-2859-4a90-b386-cdb0cac60d4a">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#160;Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#160; Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:138%"><ix:nonNumeric contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzI5_6364bd4d-13f2-44fb-b473-04cdef321722">o</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 8.01             Other Events.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 6, 2022, Cardiff Oncology, Inc. issued a press release announcing the publication of two abstracts that have been accepted for poster presentations at the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place both virtually and at the Paris Expo Porte de Versailles in Paris, France from September 9 &#8211; 13, 2022.   A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.  </span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a991ex090622.htm">Press Release of Cardiff Oncology, Inc. dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a991ex090622.htm">Sept</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a991ex090622.htm">ember</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a991ex090622.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a991ex090622.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a991ex090622.htm">, 2022.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> September 6, 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.01
<SEQUENCE>2
<FILENAME>a991ex090622.htm
<DESCRIPTION>EX-99.01
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1a2bd8ee4453403e8e114a5a71bd78e7_1"></div><div style="min-height:42.48pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:159px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SAN DIEGO, September 6, 2022 &#8211; Cardiff Oncology, Inc. (Nasdaq&#58; CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the publication of two abstracts that have been accepted for poster presentations at the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place both virtually and at the Paris Expo Porte de Versailles in Paris, France from September 9 &#8211; 13, 2022. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The full texts of the published abstracts can be found on the ESMO Congress 2022 website. Details on the corresponding posters are shown below. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.729%"><tr><td style="width:1.0%"></td><td style="width:25.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Poster Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The PLK1 Inhibitor Onvansertib Overcomes Irinotecan Resistance in RAS-mutated (mRAS) Metastatic Colorectal Cancer (mCRC) In Vivo and in Patients</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Speaker&#58;</font></div><div style="margin-bottom:10pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Poster Number&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Scott Kopetz, M.D., Ph.D.</font></div><div style="margin-bottom:10pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">366P</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Session Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Poster Session 7</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Session Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 11, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Session Hours&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9&#58;00 AM &#8211; 5&#58;00 PM CEST</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Location&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Poster Area, Hall 4</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The abstract includes findings from an Expanded Access Program (EAP) in which patients with KRAS-mutated metastatic colorectal cancer (mCRC) who failed or progressed on standard-of-care, including irinotecan, were treated with onvansertib in combination with FOLFIRI&#47;bevacizumab. These findings showed that early changes in KRAS mutant allelic frequency (MAF) were associated with increased benefit in the EAP. In addition, the abstract includes results from murine studies in patient-derived xenograft (PDX) models of RAS-mutated, irinotecan-resistant colorectal cancer. These data, together with findings from the EAP, suggest onvansertib can overcome irinotecan resistance in RAS-mutated colorectal cancer. Additional findings from the EAP and data from murine studies will be announced during the upcoming congress, in accordance with ESMO&#8217;s embargo policies. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-1-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.729%"><tr><td style="width:1.0%"></td><td style="width:25.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Poster Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Early Decreases in KRAS Mutant Allele Frequency (MAF) Predicts Clinical Benefit to the PLK1 Inhibitor Onvansertib in Combination with FOLFIRI&#47;bev in 2L treatment of metastatic colorectal carcinoma (mCRC)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Speaker&#58;</font></div><div style="margin-bottom:10pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Poster Number&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Heinz-Josef Lenz, M.D.</font></div><div style="margin-bottom:10pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">397P</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Session Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Poster Session 8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Session Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 11, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Session Hours&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9&#58;00 AM &#8211; 5&#58;00 PM CEST</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Location&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Poster Area, Hall 4</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The abstract includes data from an ongoing Phase 1b&#47;2 trial evaluating onvansertib in combination with FOLFIRI&#47;bevacizumab in second-line KRAS-mutated mCRC. The data show that the subset of patients with &#8805;90% decreases in KRAS MAF in circulating tumor DNA after one cycle of treatment had a significantly greater objective response rate and significantly longer progression-free survival compared to the subset of patients with decreases in KRAS MAF &#60;90%. Additional findings from the trial will be announced during the upcoming congress, in accordance with ESMO&#8217;s embargo policies.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical and Corporate Update Conference Call and Webcast</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cardiff Oncology will host a webcast and conference call to provide a clinical and corporate update on Monday, September 12, 2022 at 4&#58;30 PM ET. The event will feature discussions on the planned development pathway for onvansertib in KRAS-mutated metastatic colorectal cancer and updates on other development programs. In addition, company management will provide data updates from ongoing clinical trials. To access the call, please dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) and refer to conference ID 13731618. The conference call will also be webcast live and a link to the webcast can be accessed </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">here</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. A replay of the webcast will be available by visiting the &#34;</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Events</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34; section of the Cardiff Oncology website after its conclusion.&#160;</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About Cardiff Oncology, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC. For more information, please visit&#160;</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.cardiffoncology.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Forward-Looking Statements<br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as &#34;anticipate,&#34; &#34;believe,&#34; &#34;forecast,&#34; &#34;estimated&#34; and &#34;intend&#34; or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results&#59; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates&#59; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses&#59; uncertainties of government or third party payer reimbursement&#59; dependence on key personnel&#59; limited experience in marketing and sales&#59; substantial competition&#59; uncertainties of patent protection and litigation&#59; dependence upon third parties&#59; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics </font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended&#160;December 31, 2021, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cardiff Oncology Contact&#58; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">James Levine<br>Chief Financial Officer<br>858-952-7670<br></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">jlevine&#64;cardiffoncology.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Investor Contact&#58; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Joyce Allaire </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LifeSci Advisors </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">212-915-2569 </font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">jallaire&#64;lifesciadvisors.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Media Contact&#58; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amy Jobe, Ph.D. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LifeSci Communications </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">315-879-8192 </font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ajobe&#64;lifescicomms.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-3-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>crdf-20220906.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9c7e79fd-b44a-4fe9-9350-01d310b3d7b9,g:6c1a1eac-e2dc-4a93-aba9-64cc82ee1060-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:crdf="http://www.cardiffoncology.com/20220906" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardiffoncology.com/20220906">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20220906_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20220906_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.cardiffoncology.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>crdf-20220906_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9c7e79fd-b44a-4fe9-9350-01d310b3d7b9,g:6c1a1eac-e2dc-4a93-aba9-64cc82ee1060-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_fd72122a-b9a5-4080-b60a-60d8bd76bfe3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0227fee7-6eaf-40ed-a377-f1378802b1b8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_af4da141-4048-4821-8886-6837ad19844f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7d7f0da9-d7de-4948-9364-33633f5ed929_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c2ab9baa-0f43-463e-bfde-1eb1238777fd_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_abfa4f64-1310-49c3-8b9d-846daf95f45a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_6a82985f-f942-4a47-bcae-27760850caf8_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d39d1073-a37a-4a3d-b4a0-8b006f1127ed_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_20aeb03f-84d0-459c-81cc-d0972ce06294_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_55e8d164-bd32-4b39-af86-adabc606ce04_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_69daa019-9f31-42d5-ac3f-9a14b508000f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_720612d3-b852-4726-9a8d-fe16385f773d_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9e4879e4-034d-40ce-8da3-a042227b3974_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5afd3306-9617-4699-89dd-aba99b667e49_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6b87e949-eb2f-49cb-8755-513127d469ea_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f91c03b8-6062-45e3-ad75-c9f9f0061cf2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c020aab1-71e5-434f-8fbb-2e1d6ba7a610_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1e6c6a31-7d32-43d7-8a36-5ecb415c1c12_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f454ccda-e8ee-4008-a9e1-8dcbe747d4c1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d071bfa5-a10a-4b3c-92ff-7a053eaf207e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_a4234d62-6e5e-40b1-9697-9b0dd7ac82d4_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>crdf-20220906_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9c7e79fd-b44a-4fe9-9350-01d310b3d7b9,g:6c1a1eac-e2dc-4a93-aba9-64cc82ee1060-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/Cover" xlink:type="simple" xlink:href="crdf-20220906.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c9d4bdf3-0e04-40a9-b0bd-7b53f21b083c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_DocumentType_c9d4bdf3-0e04-40a9-b0bd-7b53f21b083c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9bdcea0f-9aae-4037-9408-5fde9d239152" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_DocumentPeriodEndDate_9bdcea0f-9aae-4037-9408-5fde9d239152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f118910e-de29-4c47-a8e5-ac00e787ce31" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_EntityRegistrantName_f118910e-de29-4c47-a8e5-ac00e787ce31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_61220641-eaa3-4adf-b6ba-b4177401ad9e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_EntityFileNumber_61220641-eaa3-4adf-b6ba-b4177401ad9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5b4407cf-0f57-4ced-ae88-a6bc06d1c7cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_EntityTaxIdentificationNumber_5b4407cf-0f57-4ced-ae88-a6bc06d1c7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_22c517af-b37a-4e51-a41f-4e9008931f69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_EntityAddressAddressLine1_22c517af-b37a-4e51-a41f-4e9008931f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1bb12e6a-3c98-4327-a121-2ae329775e52" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_EntityAddressStateOrProvince_1bb12e6a-3c98-4327-a121-2ae329775e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_75656ee5-3d88-43aa-88a1-31e3a5986ad7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_EntityAddressPostalZipCode_75656ee5-3d88-43aa-88a1-31e3a5986ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f7b4968b-59b1-4f3f-bec5-2f81d291f72d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_EntityAddressCityOrTown_f7b4968b-59b1-4f3f-bec5-2f81d291f72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_86bf8437-e7a3-4f89-b979-1a03ca880a05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_CityAreaCode_86bf8437-e7a3-4f89-b979-1a03ca880a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8e84141a-b747-4c1f-b76b-1f5efd4d49aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_LocalPhoneNumber_8e84141a-b747-4c1f-b76b-1f5efd4d49aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d3a1d2d9-babf-4a00-8ce6-30e80421f42e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_Security12bTitle_d3a1d2d9-babf-4a00-8ce6-30e80421f42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e6a2661d-7f5b-4233-a73b-789fab592bc1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_TradingSymbol_e6a2661d-7f5b-4233-a73b-789fab592bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_05fb24a3-c559-4cae-b34e-1996e168a19d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_WrittenCommunications_05fb24a3-c559-4cae-b34e-1996e168a19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_33f010af-df68-4209-ab61-e94d9edf3f3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_SolicitingMaterial_33f010af-df68-4209-ab61-e94d9edf3f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_7d839bd1-e59f-4d08-a4e5-699b71e78a03" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_PreCommencementTenderOffer_7d839bd1-e59f-4d08-a4e5-699b71e78a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_43c0b049-9234-409e-92da-06de1005cb23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_43c0b049-9234-409e-92da-06de1005cb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c6c0ca4f-7ce2-4eff-a2b2-49d01c374e2d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_EntityEmergingGrowthCompany_c6c0ca4f-7ce2-4eff-a2b2-49d01c374e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1e735993-4302-4f6a-8a10-5ef77dcd439e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1e735993-4302-4f6a-8a10-5ef77dcd439e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d45946e5-bdc6-4413-a8ff-09b417a01599" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_EntityCentralIndexKey_d45946e5-bdc6-4413-a8ff-09b417a01599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e47e1e50-78a5-4195-8da0-5b95d59bea9e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f50f7f0b-9a8a-4ae0-beae-c1a9675a141c" xlink:to="loc_dei_AmendmentFlag_e47e1e50-78a5-4195-8da0-5b95d59bea9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>crdf-20220906_g1.jpg
<TEXT>
begin 644 crdf-20220906_g1.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  N *8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**X.^B
MU#QQXJUG2&U&;3-$TPPQS1V9V373/&)"#)U5 & PO)YYK*I4Y$K*[>B.BC1]
MJW=V25V_*Z7YL[RBO.]9\$KX#TJ]UCPI=RZ4;.%[B73Y'::UN0JEB&5B2K$#
M[RD5T+>.+-;>SVP7-W=W%NERUK9Q&5XT90<MV Y^I["N>6*C2O[?W?GH_3_A
MC:6%YDI4'S)^5FO5:K\6='15/2]6M=:LUNK.430L2,X(((Z@@\@CT-7*ZHSC
M4BI0=TSCE%Q;C)6:"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKA;[^TO!?BC5]833I-6T;4S#)/\ 8^;BU=(Q'GR_XU(4'Y>1SP:[JBLJE/G2
ML[-:HZ*-;V3=U=-6:\KI_FCR_P :?$JTUCPWJ-KI0"V4\#07.L:B&MK2V#J0
M>7 9WP>$4'G%0>#?&5C_ &M=1Z W]MF2V@5[5P;2Z3RX]JR>7*%W1L,'<.F:
MT?BFUOIOB+P?K6J6[3:#I]Q<-=R>09D@9HL12.H!P V?FQP2*SO%FOZ1XT\9
M>#;?P[<0ZOJ=CJ4=Y<W5B/,6WM/*D#AY5X4,67Y<\\<5G+ ^V2G*;YEJFK:;
MK9I]&[W[G+4S1TI.C3BE!-+E=W*5[:W36W2RZ,ZA-6LOAWX=U'6?%.H6>D03
M7+7,KR2_)&6P%C!/+-QT R2< &D\&?%SPG\0-0N+#0]6^TW]O'YTEI/;RVTP
MCW;=X25%8KGC< 1R/45QOBJW@U_]IGPGINKJLVG:?H-SJNG6\P!C>^\^.,O@
M\,Z1G([KN)%=7\6/%]QX+\.P7.EVT%QK^HWEOI&G?:%/EK-<2A%9R.=B\N1W
MV8XSD:4:4:,%3CT-JE1U).;ZG;T5\O\ Q \>>+/ >I>/[#3O&-]KESI/A^Q)
MDNH;9?)U*ZN_+38J1 *-FTA3N^^,YZUW5R/%EUXXLO!#^+KN&6XLY=?U74[:
M"%)(8]Z11VEIE"$CWAV+.'? ^]EN-C,[J;XI>&K?5I]-EU!H[N+5(=%*^1(0
M;R6(2I$"%(Y0@YZ#H3FIYOB/X<@U;5=.?4@L^DP&YU"7RI/L]H@4,1+/M\M&
MVD-L+!L<XQS7S_\ "7Q%J;:YHD.GZ[/>VWBCQGK5S<:B8XP][:6ML8D8[5"C
M+1Q'Y0!GL!Q7.-X/OM2^ NHW/_"6Z[.?%WBX68@E-L4F5]4^S[V_<9+-&FXX
M(&57 "Y4@'UIX=\26/BK2(M3TYIVLI<['N+66W+ '&X+(JMM/9L8(Y!(KD+?
M]H+X>W6J+81^)K=F:7R%NO*E%FTF<;!<E?)+9XP'SFN<_:#2]\*_ '4+/^U]
M0OU:6UL[W5+ED%R;:6ZC29F:-44?([+D*, _C6_\8K/P_P"'_@1XHL9K.WAT
M2+2);:"SC0!"Q0K#'&!_$7*!<<[B,<T >CT5\T:%J'C[5)O%>D77BNZT/3_"
MOAW3/M4UO%"UT;[[$99 &D1@%)8%\C<<(%*Y;.WX%\7>*_C%-HVE-KMSX;CL
MO#.FZKJMYIL4(N;J[NXV9%7S$=4C41LQPN26 X Y /?*Q[KQ9IMGXIT_P[+,
MPU:^MIKN&%48@Q1% [%L8',BCGKFO+;G4O$7BG7O&&GQ^-+KP_8>#;2&W>^@
MM[<O>7C6PG>XF#QE1$JLH\M N3O.0,5YW/\ %K5EO(_'TUE$VM6GP]L&6!N(
MEN]0O%5"1V7,:,1UVG% 'U=17@WB36/'/PZ\1#1M,U^Z\<:K?^&M2U$6=];P
M*8+N#RO*>,1(IV2-(RB-L\J,'K63H=YXV\4:AXDMO#_C;Q%<QV/AL2%M2TV"
MW/\ :\BOY:*KVROL 4,0O .!D\B@#Z/HKQGX>_$;4_C-JVD7.DWCV6@V6BQW
M&JR0J/WNH7,*E+?.,CR4)=MI'+QCUKU;2=/N=/$PGU":_5FRGG*H,8R3M! Y
M'('//')-(#0HHHH **** $(# @C(JMI^EV6DPM%8VD%G$S%REO$L:ECU. .M
M6J*!65[G,>-_AQH/Q"CL1K%K(US82&:SO;6XDMKFU<C!,<L;*ZY  (!P<#/0
M5C_\*+\(-H=]ILEG>7!O9X;N?4+C4;B2^::(YBD^TLYD#(?NX88R<=3GOZ*!
MG 1_ OP=%!>Q+ITI%[)9RW3O=2O)</;2M+$\CLQ9VWLS,6)+$\YK3\5?"WP[
MXTUFUU74[69KZWMWL_-M[N6#SK=R&:&41L/,C) .ULCKZG/644 <AH_PJ\.>
M';C2+C3;'[/+I'VTV(\URD1NY!).<9YRPXST' Q7/Z7\%AIW@?X?^'&U3S4\
M,ZA;ZA<3>3@WDD:R-P,_+F5U?OPN/>O3Z* *FJZ59ZYIEUIVH6T=Y8W430SV
M\RADD1AAE([@@UQ6B_ OPEHFH65TL&H7ZV#A[&UU34[F\MK-A]UH8I9&1".Q
M R.V*] HH YK_A7FB>7XJ3[/)CQ-G^TV\YMTN81#P<_+\B@<8QUK$U?X&^%-
M8NK"X,6H:?+:64>F%M,U*XM#<6J#"P3&)U\Q![\^]>@44 <)K7P1\(:]?27%
MQ83QI/%#!=6EK>30VUY'$,1+/$CA) HX 8'C@Y'%:.H?"_PUJTWB&2]TU;D:
M]:P65_&[MLDAA#^6J@'Y,;V.5P<X/85U5% 'E?B+X.R:;X?NSX1NKS^V[F:V
M^V7>I:O<M=7EK$^6M1=L7DA!!;!3H2>Y)J/P'\/==\+ZYXJ\2)8V6FW6H6$-
MM:Z,FISWD<DL/F%99YY%!!)<+A5P%&?F)X]8HH X[X3_  ]@^&/@BRT6/RGN
@MSW-[/"FQ9KF1B\K@=EW'"CLJJ.U=C110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@  "#P   )$" (   !_LS'E    "7!(67,  40P
M  !9,@$<[ &S  !%KDE$051XG.S<08X<R](FUMZAH)D$S;277HF@#6A56H#F
M)1#W@H^/+&9%97BX?69^#G+4X*LP,_>(C/3OO_T_/@        +\C^H"
M    ?A!:        $806      ! !*$%       006@!      !$$%H
M   1A!8      $ $H04      !!!: $      $006@       !&$%@
M0 2A!0      $$%H 0      1!!:        $806      ! !*$%       0
M06@!      !$$%H        1A!8      $ $H04      !!!: $      $00
M6@       !&$%@      0 2A!0      $$%H 0      1!!:        $806
M      ! !*$%       006@!      !$$%H        1A!8      $ $H04
M     !!!: $      $006@       !&$%@      0 2A!0      $$%H 0
M    1!!:        $806      ! !*$%       006@!      !$$%H
M   1A!8      $ $H04      !!!: $      $006@       !&$%@
M0 2A!0      $$%H 0      1!!:        $806      ! !*$%       0
M06@!      !$$%H        1A!8      $ $H04      !!!: $      $00
M6@       !&$%@      0 2A!0      $$%H 0      1!!:        $806
M      ! !*$%       006@!      !$$%H        1A!8      $ $H04
M     !!!: $      $006@       !&$%@      0 2A!0      $$%H 0
M    1!!:        $806      ! !*$%       006@!      !$$%H
M   1A!8      $ $H04      !!!: $      $006@       !&$%@
M0 2A!0      $$%H 0      1!!:        $806      ! !*$%       0
M06@!      !$$%H        1A!8      $ $H04      !!!: $      $00
M6@       !&$%@      0 2A!0      $$%H 0      1!!:        $806
M      ! !*$%       006A!L?_W?_Z?5S[590(     \#BA!04N!A4R#
M  " HP@MV.=^5B&]       83&C!#D_$%:(+     (!AA!8\Z^FX0G0!
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MEL'G^X-; P     XA-#B%"5G^IN/]4_H$0    !@,*'%$8XZRC^J60    "
M2806PQU[@G]LXP      ?0DMQG)J_V$(      "M""T&*CFICSVL-PT
M@"Z$%M,XH/^4L0      Y!-:S.%<_DM&!     "03&@Q@;/XZTIFU7=<
M   ["2UZ<P3_'G,#      @DM&C,L?M-!@@     $$5HT9+3]H4,$P     @
MA-"B&2?L3RB9Z@F#!0    #X%J%%)P[6'V6\      "UA!8].$_?QIP!
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M     %PDM*CG4'L\2PP     <(70HI[C[!-890    " +PDMZCG+/H2%!@
M  !X36A1S/\!_CDL-     # :T*+8@ZRCV*Y 0    !>$%H4<X1]%*$%
M , +0HMBCK!/8\4!     /Y&:%',$?9IK#@     P-\(+8HYOSZ01?_I__M_
M_M?7G^H" 0   ("MA!:5_!_=G\FB?YE52"\     X$Q"BTI"BS,=N^AO9!6B
M"P     XBM"BDM#B3&>N^_W$0G0!     .,)+2J=>7C-:>N^,*X070    #
M;$*+2J<=7O./<];]H;A"= $     4PDM*IUS>,VO3ECW#7&%W (     YA%:
M5#KA\)H_C5_WG8F%Z (     )A%:5!I_>,VG!J][25PAN@    " ,806E08?
M7O/"R'4OCRM$%P     P@-"BTLC#:[XT;]W+4PJY!0    #,(+2H-._PFBLF
MK7MY."&Z     (!)A!:5)AU><]V,=2\/)$07     #"/T*+2C,-KOJO[NI>'
M$*(+     )A*:%&I^^$U[VF][N79@]P"      836E1J?7C-VYJN>WGD(+H
M    @/&$%I6:'EYS4[MU+X\91!<     < BA1:5VA]<LT6C=RZ,%T04
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M      XAM*@DM#C3U-#B?FU+C&\0      836E026IRI<-T/.= _I$T
MF$=H44EH<:9AH<62F3SAJ&8!    8 :A126AQ9FJUOW,$_PSNP8   " IH06
ME8069QH06JP:Q38G]PX     C0@M*@DMSM0]M%@UA\T.;Q\     6A!:5!):
MG*EO:+%J H4, 0    "2"2TJ"2W.5++N3NI_91H     D$EH44EH<2:A13G3
M     (!,0HM*0HLSM0LM%O:>PT      ()#0HI+0XDQ"BP0& @    "!A!:5
MA!9G$EHD,!      ""2TJ"2T.)/0(H&!     $ @H44EH<69A!8)# 0
M @DM*@DMSB2T2& @     !!(:%%):'$FH44" P$   " 0$*+2D*+,PDM$A@(
M      026E026IQ):)' 0      @D-"BDM#B3$*+! 8"     (&$%I6$%F<2
M6B0P$      ()+2H)+0XD] B@8$     0""A126AQ9F$%@D,!      ""2TJ
M"2W.)+1(8"      $$AH44EH<2:A10(# 0   (! 0HM*0HLS"2T2& @
M!!):5!):G$EHD<!      ""0T**2T.),0HL$!@(     @806E8069Q):)# 0
M      @DM*@DM#B3T"*!@0    ! (*%%):'%F806"0P$      ()+2H)+<XD
MM$A@(      02&A126AQ)J%% @,!    @$!"BTI"BS,)+1(8"      $$EI4
M$EJ<26B1P$      ()#0HI+0XDQ"BP0& @    "!A!:5A!9G$EHD,!
M""2TJ"2T.)/0(H&!     $ @H44EH<69A!8)# 0      @DM*@DMSB2T2& @
M     !!(:%%):'$FH44" P$   " 0$*+2D*+,PDM$A@(      026E026IRI
M9-&=T?_&0      @D-"BDM#B3$*+! 8"     (&$%L6$%J>I2JJ<T?_&0
M   @D-"BF/_8XC1"BQ & @    "!A!;%A!:G$5J$,!      ""2T*';G"%MN
MT4[A<CNC_XV!     $ @H44QH<51A!8Y# 0      @DMBMT\Q99;-%*[T,[H
M?V,@     !!(:%%/:'$(H46..],8.1      ""&TJ.<_MCA!^2H[IO^5:0
M  ! )J%%O?O'V7*+<"'K>_.D?L9AO2$     0#*A102YQ6 YBWO_O+[[J?WA
M[0,   ! /J%%A"7GVJ*+-&G+NBJTZ'AP?W+O     -"(T")%V@$W-P4NZ,*#
M^T;']V=V#0    !-"2U2+#SC%EW42E[*Y2?XR8?X1S4+     #,(+8(L/^P6
M76R6OX)/G.-G'N6?TRD     3"*T"/+$D;?<8H^'UNZ)Y7OH-#_G0']\@P
M   PF- B2Z.S;W[JM6K/G>F7G^P/;@T     #B&TR/+<\;?HX@E-%^OIP_W]
MY_OS.@(   " ,PDMXCR=6X@NEFB]3!N.^'>>\@]K!P    !.)K1(U/I ?+P-
MJ[-A@?8<]#]]UC^C"P    #@)Z%%J!DGX_-,6I=M)_Y/'/JW+AX     ^!NA
M1:X]Y^.BBXM&+L?.H_]5I_\=:P8     +A):Y-IV2BZZ>&WV*O3* 'I5"P
M  !\E] BFMRBW E+L#D)>"\,:%$D     '"3T"+=YD-ST<5/1XU]?R1P/15(
MK@T     6$MHT8/H8J<SIQV8#924)+$     @$)"BS;VGZ2''*;O9,@Y(4%.
M)0    # -D*+3ARI/\IX?RK\3QP*+PT     E!-:].-L?3DC_5-5>""Q
M ("3"2U:*CEDSS]G?X,QOE8>)X@K     . H0HO&'+C?(?BYKCQ:$%<
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MR@\#\BM<8EM<T2NZV%GA;-O.1_S,@"JU=^CXA\.,9^.,+OK:]K5KI8!,GF
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M%KRI/'7H$E=\3$DL1!<YRD\N')1 K)(;;<8M/^,1-Z"%1JKVS(R]"AS+4PB
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MMZ27,=-;ZX2Q5/7H0?&0;3VV&&.+(M^N<VVIY07 >X06\,/]T_:.!^YKG3G
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M9'DOY07<ES#&DN(W-)500]_R+IK118BT.RA3^)0"2WI;52^9*YM@V&02VE'
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M9Y$MQA)>9%I5R;-:4N'F^['<^/DLV0]]VX>_$5I 2[**=IYX$2E\+TFKO[R
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M,=YT0H]PG= "H%+YV]NPE\7R!M_NNG"8L:NY1/GJWQ]@[=*$;X_P\BZ:T<4
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MT04 D.F]-XT6+QM]^^I;.>PGM   H),9/_9F= $ 9)H:6O3MJVG94$5H 0!
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MH04  %3R,Q4 >-J>V*#P4SW@_QC0 I036@    # <.6YPOBXXA\SNH!:0@L
M    F*\\8)!8=&D$:@DM     . (Y3'#X,3BPW]F 8L(+0    #@%.5AP\BX
MXL-_9@'K""T     X"SEP<.\(_YA[4 AH04     '*<\?IATOC^O(R@DM
M  " 0Y5'$0,.]Z?V!56$%@    !PNO)DHN^9_NSN8#^A!0    #P0WE0T>Y
M?W9W4$)H 0    #\%T'%12?T")L)+0    " OQ)4 #L)+0    " JT04P*.$
M%@      0 2A!0      $$%H 0      1!!:        $806      ! !*$%
M       006@!      !$$%H        1A!8      $ $H04      !!!: $
M     $006@       !&$%@      0 2A!0      $$%H 0      1!!:
M    $806      ! !*$%       006@!      !$$%H        1A!8
M $ $H04      !!!: $      $006@       !&$%@      0 2A!0
M$$%H 0      1!!:        $806      ! !*$%       006@!      !$
M$%H        1A!8      $ $H04      !!!: $      $006@       !&$
M%@      0 2A!0      $$%H 0      1!!:        $806      ! !*$%
M       006@!      !$$%H        1A!8      $ $H04      !!!: $
M     $006@       !&$%@      0 2A!0      $$%H 0      1!!:
M    $806      ! !*$%       006@!      !$$%H        1A!8
M $ $H04      !!!: $      $006@       !&$%@      0 2A!0
M$$%H 0      1!!:    _W][=BP     ,,C?>AH[2B,  ( %:0$      "Q(
M"P      8$%:        "]("      !8D!8      ,""M        !:D!0
M    L" M      " !6D!       L2 L      &!!6@        O2 @
M6) 6      # @K0        6I 4      + @+0      @ 5I 0      +$@+
M      !@05H        +T@(      %B0%@      P(*T        %J0%
M  "P("T      ( %:0$      "Q("P      8$%:        "]("      !8
MD!8      ,""M        !:D!0      L" M      " !6D!       L2 L
M     &!!6@        O2 @      6) 6      # 0NM#.\ATCB[O     $E%
&3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140033264612208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 06, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  06,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardiff Oncology,&#160;Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-2004382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11055 Flintkote Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-7570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRDF<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>crdf-20220906_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crdf-20220906.xsd" xlink:type="simple"/>
    <context id="i6c087b6a4e944acea515703fcc182477_D20220906-20220906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2022-09-06</startDate>
            <endDate>2022-09-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM180L2ZyYWc6ZmE2ZWJjZDgxOWQ2NDI4M2JiZTk4MzkwNjU4MmU0ODAvdGFibGU6MWYwNGVkYTNjZWJiNDUwMTk3ZjliZWYyZmNlOTBlOWEvdGFibGVyYW5nZToxZjA0ZWRhM2NlYmI0NTAxOTdmOWJlZjJmY2U5MGU5YV8yLTEtMS0xLTM3MjIw_2b8aedcc-909c-446d-b57c-9133a06e61c4">0001213037</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM180L2ZyYWc6ZmE2ZWJjZDgxOWQ2NDI4M2JiZTk4MzkwNjU4MmU0ODAvdGFibGU6MWYwNGVkYTNjZWJiNDUwMTk3ZjliZWYyZmNlOTBlOWEvdGFibGVyYW5nZToxZjA0ZWRhM2NlYmI0NTAxOTdmOWJlZjJmY2U5MGU5YV8zLTEtMS0xLTM3MjIw_ca57b290-39eb-4c0b-9b91-372f5d0aa471">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzM0_204f5138-f954-4f21-abbb-3828ea4f9863">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF8yMjg_62a18123-97c5-4d0c-bf92-7e9349a52e3e">2022-09-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzMw_b43a5dcf-e0df-4506-b822-6574e5ed9dd5">Cardiff Oncology,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGFibGU6MjcxYWJhNTIwYzNiNDVmNGI0YWQyMDc3YTViZjFhNjEvdGFibGVyYW5nZToyNzFhYmE1MjBjM2I0NWY0YjRhZDIwNzdhNWJmMWE2MV8wLTAtMS0xLTM3MjIw_893462a9-5ed2-4350-950f-af6f3cb90d6f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGFibGU6MjcxYWJhNTIwYzNiNDVmNGI0YWQyMDc3YTViZjFhNjEvdGFibGVyYW5nZToyNzFhYmE1MjBjM2I0NWY0YjRhZDIwNzdhNWJmMWE2MV8wLTEtMS0xLTM3MjIw_762cddde-8cbb-40bc-a265-47c8e08ffcb4">001-35558</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGFibGU6MjcxYWJhNTIwYzNiNDVmNGI0YWQyMDc3YTViZjFhNjEvdGFibGVyYW5nZToyNzFhYmE1MjBjM2I0NWY0YjRhZDIwNzdhNWJmMWE2MV8wLTItMS0xLTM3MjIw_dddf9276-95e7-47ef-bae9-a13549b061cf">27-2004382</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzM1_c87f186d-086f-4f22-9716-7805aecd464e">11055 Flintkote Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzMz_677d2d4b-e8d7-48f2-9f76-685482342ec4">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzM2_3232843f-8471-42ec-b6f0-bd9db3a1fbf2">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzM3_53ff5cae-d5a5-4e09-8824-0137d34430c6">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzI2_603c1e02-1719-4579-8f49-a097c1b5b416">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzM5_a524b461-8425-43ba-83e6-a69bee302783">952-7570</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGFibGU6NmFmOGVhZGZiMDQzNDU0M2IzNGYyMDNjYzU5ZjgzYTYvdGFibGVyYW5nZTo2YWY4ZWFkZmIwNDM0NTQzYjM0ZjIwM2NjNTlmODNhNl8xLTAtMS0xLTM3MjIw_77ebe5e1-1b26-4f68-8496-dc9e4bc5ebdd">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGFibGU6NmFmOGVhZGZiMDQzNDU0M2IzNGYyMDNjYzU5ZjgzYTYvdGFibGVyYW5nZTo2YWY4ZWFkZmIwNDM0NTQzYjM0ZjIwM2NjNTlmODNhNl8xLTItMS0xLTM3MjIw_40433afd-25b8-42fb-b7b9-88a21b8cc2e8">CRDF</dei:TradingSymbol>
    <dei:WrittenCommunications
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzI3_f8c13b7c-8bf7-417d-870f-b28f1c1f0e2b">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzMx_67a6bebc-6d52-48ed-8edb-5a794d2676be">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzI4_070746e8-89c6-447c-aaf1-e5e92f1d6e05">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzMy_c5e7b990-2859-4a90-b386-cdb0cac60d4a">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6c087b6a4e944acea515703fcc182477_D20220906-20220906"
      id="id3VybDovL2RvY3MudjEvZG9jOjFjYjQ4MDhjZWQ3YjRmZjFhNTA5MjYzZTM4YjYzZjEzL3NlYzoxY2I0ODA4Y2VkN2I0ZmYxYTUwOTI2M2UzOGI2M2YxM18xL2ZyYWc6ZTgxYzA5ZWQyOGU0NDE1YWI2MzQ0ZGJhMGE0ZTAxMWQvdGV4dHJlZ2lvbjplODFjMDllZDI4ZTQ0MTVhYjYzNDRkYmEwYTRlMDExZF80MzI5_6364bd4d-13f2-44fb-b473-04cdef321722">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<RG:&#[%_7FA,A$+Z];G*SB4%JQ]A7"53I[&X2ENR'/-SV-8'@X6N=O@<)G
M5NQ[FAXI<ERODZPQ=(K;[__('HPI@:P3$)?M @P;8P]/,O:[G.N5R^=OH&#7
MKM@*)EO?Q [!3K3&U\.3?!UV34H72E=U?_!-G*E26KT]ZJL=ZK=W&.3!EA^W
MYSWD#'*KP5T?(*VOY#-O7SE<*H!-64A[06^ D35V'^)./85Z2ZJ:N\_8JI4'
M%SB:2?_@I.9.O5^9JQU#,IZ"4' Q &?4NX/DKF-541W>ELK"4;!JKN'PS;4;
M /=3!=NH?<>=!^OC_.0_4$L#!!0    ( /. )E6?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M 5!+ 0(4 Q0    ( /. )E4'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ \X F5;=/^,?N    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ \X F59E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " #S@"950P@PWAH$  #:#P  &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ \X F59^@&_"Q @  X@P   T              ( !70P  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " #S@"95EXJ[',     3 @  "P
M@ $Y#P  7W)E;',O+G)E;'-02P$"% ,4    " #S@"95JL0B%C,!   B @
M#P              @ $B$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M\X F520>FZ*M    ^ $  !H              ( !@A$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ \X F5660>9(9 0  SP,  !,
M             ( !9Q(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  L1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>21</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="crdf-20220906.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="crdf-20220906.htm">crdf-20220906.htm</File>
    <File>a991ex090622.htm</File>
    <File>crdf-20220906.xsd</File>
    <File>crdf-20220906_lab.xml</File>
    <File>crdf-20220906_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>crdf-20220906_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="21">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "crdf-20220906.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "crdf-20220906.htm"
     ]
    },
    "labelLink": {
     "local": [
      "crdf-20220906_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crdf-20220906_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "crdf-20220906.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 22,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 21,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "crdf",
   "nsuri": "http://www.cardiffoncology.com/20220906",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220906.htm",
      "contextRef": "i6c087b6a4e944acea515703fcc182477_D20220906-20220906",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.cardiffoncology.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20220906.htm",
      "contextRef": "i6c087b6a4e944acea515703fcc182477_D20220906-20220906",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-22-024362-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-024362-xbrl.zip
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M#XQ2Z6PR*2(O/!@&RHP;CI-*/(O&TML-Q#7.AO^)]5U[C<'=F.HA=ZFCSHA
ME(.$" B!F,3BD?:4.:X$3-)<>M7X,$AFWW<<+^PL^#BO7!UOZM@GH&^QG]6W
M51L?^@X*3H!<:LV)X!2#"*DA6#-1@AMHI;SS@D_R%/QOG1C&R^P[DM,)/0MN
MSE"Z:,ISG!KO?X&'W NI18H+I_4N)4(PW'=E2#_5W?-^0QE&-P$IWY@=]@^J
M&?<KQXNY9QI.<9WTW5KYKC3K'(0"!I+B=MM((IB6)/,&,;9:>JE1DI'SQ9:Y
M8=F?<<MR=_$FR_J;U0OQ+O#$R<'3%]U+]X_HDX/_ 5!+ 0(4 Q0    ( /.
M)E7%'7$1GQ   (E<   0              "  0    !A.3DQ97@P.3 V,C(N
M:'1M4$L! A0#%     @ \X F5:R8PN#($P  "9<  !$              ( !
MS1   &-R9&8M,C R,C Y,#8N:'1M4$L! A0#%     @ \X F5=Q4?3YM @
M@P<  !$              ( !Q"0  &-R9&8M,C R,C Y,#8N>'-D4$L! A0#
M%     @ \X F5:?6J^\#"@  K H  !0              ( !8"<  &-R9&8M
M,C R,C Y,#9?9S$N:G!G4$L! A0#%     @ \X F5<23Y*GQ"0  6UD  !4
M             ( !E3$  &-R9&8M,C R,C Y,#9?;&%B+GAM;%!+ 0(4 Q0
M   ( /. )E7A;$X9> 8  -\N   5              "  ;D[  !C<F1F+3(P
D,C(P.3 V7W!R92YX;6Q02P4&      8 !@"$ 0  9$(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
